Loading company…
SynOx Therapeutics is developing emactuzumab to treat TGCT and related diseases.
Founded in 2020 in Dublin, SynOx Therapeutics is developing emactuzumab, a monoclonal antibody targeting CSF-1R for tenosynovial giant cell tumors and related diseases. The company received venture funding from MaasInvest and is led by CEO Ray Barlow as of July 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in